JP2020518588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518588A5 JP2020518588A5 JP2019559715A JP2019559715A JP2020518588A5 JP 2020518588 A5 JP2020518588 A5 JP 2020518588A5 JP 2019559715 A JP2019559715 A JP 2019559715A JP 2019559715 A JP2019559715 A JP 2019559715A JP 2020518588 A5 JP2020518588 A5 JP 2020518588A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- protein
- fusion molecule
- subject
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492373P | 2017-05-01 | 2017-05-01 | |
| US62/492,373 | 2017-05-01 | ||
| PCT/US2018/030370 WO2018204312A1 (en) | 2017-05-01 | 2018-05-01 | Type i and type iii interferon fusion molecules and methods for use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518588A JP2020518588A (ja) | 2020-06-25 |
| JP2020518588A5 true JP2020518588A5 (enExample) | 2021-06-10 |
| JP7607895B2 JP7607895B2 (ja) | 2025-01-06 |
Family
ID=64016582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559715A Active JP7607895B2 (ja) | 2017-05-01 | 2018-05-01 | Ｉ型およびｉｉｉ型インターフェロン融合分子ならびにこれらの使用のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11292823B2 (enExample) |
| EP (1) | EP3618618A4 (enExample) |
| JP (1) | JP7607895B2 (enExample) |
| AU (1) | AU2018261750A1 (enExample) |
| CA (1) | CA3061864A1 (enExample) |
| WO (1) | WO2018204312A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12421288B2 (en) | 2023-03-16 | 2025-09-23 | A-Alpha Bio | Interferon alpha-2 variants |
| WO2025038726A2 (en) | 2023-08-14 | 2025-02-20 | A-Alpha Bio | Interleukin 21 variants |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939286A (en) | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
| CA2454860A1 (en) * | 2001-08-12 | 2003-02-27 | Pepgen Corporation | Hybrid interferon/interferon tau proteins, compositions and methods of use |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| CA2574564C (en) * | 2004-07-29 | 2013-04-16 | Zymogenetics, Inc. | Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| RU2562108C2 (ru) * | 2007-09-20 | 2015-09-10 | Коммонвелт Сайентифик Энд Индастриал Рисерч Органайзейшн | Новые цитокины птиц и кодирующие их генетические последовательности |
| CN102212539B (zh) | 2011-04-08 | 2012-10-24 | 山东省农业科学院畜牧兽医研究所 | 高效表达的串联猪α、γ干扰素基因及其表达蛋白的用途 |
| LT6164B (lt) * | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| CN106674354B (zh) | 2017-02-14 | 2020-10-16 | 华南农业大学 | 一种鸡干扰素IFN-λ与IFN-α的融合蛋白 |
| CA3070230A1 (en) | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
-
2018
- 2018-05-01 WO PCT/US2018/030370 patent/WO2018204312A1/en not_active Ceased
- 2018-05-01 AU AU2018261750A patent/AU2018261750A1/en not_active Abandoned
- 2018-05-01 CA CA3061864A patent/CA3061864A1/en active Pending
- 2018-05-01 US US16/604,666 patent/US11292823B2/en active Active
- 2018-05-01 JP JP2019559715A patent/JP7607895B2/ja active Active
- 2018-05-01 EP EP18793791.7A patent/EP3618618A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533858A5 (enExample) | ||
| JP2019519553A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2012505837A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| JP2009504157A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| JP2013504545A (ja) | Ｃｘｃｌ８媒介肺炎症の治療のための組成物 | |
| JPWO2019107530A1 (ja) | 炎症性腸疾患の治療薬 | |
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| JP2017529326A5 (enExample) | ||
| JP2014530873A5 (enExample) | ||
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases | |
| JP2014506231A5 (enExample) | ||
| JP2020518588A5 (enExample) | ||
| FI4009978T3 (fi) | Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon | |
| JP2023517616A (ja) | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 | |
| JP2017536380A5 (enExample) | ||
| JP2017507145A5 (enExample) | ||
| Güler et al. | Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics | |
| EP3215193B1 (en) | Dosage regimen for pegylated interferon | |
| JP2011503008A5 (enExample) | ||
| JP2009514794A5 (enExample) | ||
| US20240158798A1 (en) | Non-viral gene/carrier complex for prevention or treatment of acute inflammatory disease | |
| CN115697377A (zh) | 涉及治疗疾病的组合物和方法 |